Join Yan Kugel from Qualistry as he interviews Alberto Catapano, Key Account Manager at NTC Pharma, at CPHI. Discover how NTC Pharma is driving innovation in the pharmaceutical industry with a strong focus on research and development in ophthalmology, gynecology, and beyond. Alberto shares insights into their latest projects, including novel treatments and preservative-free formulations, as well as the company’s commitment to corporate social responsibility and sustainability. Learn about the challenges NTC Pharma faces in a rapidly evolving market and their strategies for growth and innovation.
Commitment to Research and Development
At the heart of NTC Pharma’s mission is a strong dedication to R&D. The company has made significant strides, particularly in ophthalmology, where it has experienced double-digit growth with its fixed-dose combination treatments for post-cataract surgery, now available in over 50 markets. One notable advancement is NTC014, a novel treatment for bacterial conjunctivitis. Additionally, NTC is expanding its portfolio of preservative-free formulations to meet the evolving needs of patients.
In gynecology, NTC Pharma employs its patented TIAB technology, which utilizes silver ions to combat bacterial infections. Their focus on innovation is clear: they aim not just to advance medical science but also to create a positive global impact.
Strategic Partnerships for Enhanced Capabilities
NTC Pharma collaborates with over 37 qualified Contract Manufacturing Organizations (CMOs) across the European Union, primarily centered in Italy. These partnerships are crucial for maintaining agility and efficiency in delivering innovative solutions to the market. Alberto highlighted the importance of these relationships, stating that they allow NTC to customize products for each partner while staying responsive to market demands.
Current technological focuses include preservative-free formulations in ophthalmology and controlled release technologies in both gynecology and gastroenterology. These advancements are pivotal as the company aims to strengthen its market position through strategic collaborations.
Commitment to Corporate Social Responsibility
NTC Pharma integrates social and environmental considerations into its operations, reflecting a deep commitment to corporate social responsibility (CSR). In 2023, the company completed an Environmental, Social, and Governance (ESG) assessment, confirming its alignment with international best practices. Following this assessment, NTC’s board approved a comprehensive ESG action plan.
The company’s environmental efforts are noteworthy—100% of its electricity is sourced from renewable resources, and 37% of its turnover comes from green products. On the governance front, NTC has established a third-party code of conduct and ensures all employees are trained on anti-corruption policies. This commitment goes beyond compliance; it embodies the company’s ethos and operational philosophy.
Navigating Industry Challenges
The pharmaceutical sector is fraught with challenges, including regulatory changes and global supply chain disruptions. Alberto noted that NTC Pharma has faced hurdles adapting its medical device portfolio to comply with the new European Medical Device Regulation (MDR). By bolstering internal resources and maintaining close relationships with manufacturers, NTC has successfully navigated these challenges, already obtaining several CE certificates under the new MDR.
To address global supply chain issues, NTC has consolidated its manufacturing network and enhanced logistics flexibility to ensure operational continuity.
Future Priorities: Innovation and Market Expansion
Looking ahead, NTC Pharma’s priorities center on innovation, partnership building, and global market expansion. The company is dedicated to expanding its R&D pipeline with preservative-free formulations and fixed-dose combinations that address unmet medical needs.
NTC Pharma aims not only to enhance its product offerings but also to set new standards in effectiveness and sustainability. Their commitment to implementing ESG principles will guide their growth strategy, ensuring that benefits extend not only to patients and partners but also to the broader community.
Conclusion
NTC Pharma exemplifies how a strong commitment to innovation and corporate responsibility can lead to meaningful advancements in healthcare. With a focus on R&D, strategic partnerships, and sustainable practices, NTC is well-positioned to continue making significant contributions to the pharmaceutical industry while improving patient outcomes worldwide.
With a dedication to serving the pharmaceutical industry, Qualistery specializes in hosting informational webinars that support both professionals within the pharma sector and service providers. Our commitment lies in empowering businesses to maximize their impact through engaging virtual events and strategic webinar solutions. Additionally, Qualistery supports life science companies through private GxP training and compliance services.
